# Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome

> **NCT07729592** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 44 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Donafenib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07729592
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-07
- **Final completion:** 2029-07
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07729592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07729592, "Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07729592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*